Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient base – something CEO George Scangos has learned a lesson or two about by now. Two years ago, Biogen famously halted Phase 3 […]
A study by a team of researchers from Biogen and PatientsLikeMe to quantify physical activity of patients with multiple sclerosis between doctor appointments released some details on the patient experience of the study. It found the experience resonated with many of the participants keen to use the FitBit One to monitor their own activity. Participants […]
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
As part of an effort by Biogen idec to explore ways to use wearables with MS patients to help physicians quantify patient activity, it recently completed a study of 250 patients in collaboration with PatientsLikeMe, Naomi Fried, vice president of medial information and innovation at Biogen, referenced the study as part of a keynote presentation […]
Naomi Fried, Boston Children’s Hospital chief innovation officer, today said she is stepping down from her position to join Biogen Idec as vice president of medical information, innovation and external partnerships. Fried told colleagues of the move to the Cambridge-based pharma company in an internal email today, saying it was a “hard decision” to leave […]
A biotech startup formed by Atlas Venture is collaborating with Biogen Idec to develop a treatment for inherited forms of Ataxia– a degenerative neurological condition that leads to physical disabilities, according to a company statement. They include the loss of coordination of hands, fingers, arms, legs but it can also cause a curvature of the […]
(Reuters) – Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company’s experimental long-acting medicine for hemophilia. Biogen, which is developing the drug in partnership with Swedish Orphan Biovitrum AB, said it had provided the FDA additional information related to validation of […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
WASHINGTON, March 29 (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such a...
Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain infection that affects some patients using the drug. The U.S. Food and Drug Administration today cleared the blood test which can help doctors determine whether […]
Samsung Biologics, the drug manufacturing business that a South Korean conglomerate formed earlier this year with the help of pharmaceutical services firm Quintiles, is partnering on a $300 million initiative with Biogen Idec (NASDAQ:BIIB). The joint venture, which will be based in South Korea, will develop, manufacture and market biosimilars, biological products that are similar […]
Current medical news from today, including BIIB stocks close at year high after MS drug succeeds in Phase 3 clinical trials, FDA funds research for approval process reform, and a new approach to chemotherapy for breast cancer.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Biogen Idec (NASDAQ:BIIB) is on track to add a third multiple sclerosis therapy to its portfolio — one with blockbuster drug potential. The biotechnology company on Wednesday reported positive results from the second of two phase 3 trials on its MS drug candidate BG-12. In a two-year study, a twice daily dosage reduced the annualized […]
Biogen Idec (NASDAQ:BIIB) has received European approval on an injectable pen that delivers its top-selling multiple sclerosis drug Avonex. Avonex is used as a treatment for relapsing forms of MS. The drug slows the progression of physical disability and reduces relapses. Weston, Massachusetts-based Biogen Idec makes Avonex at a manufacturing facility in North Carolina’s Research […]